Corrigendum [0.03%]
勘误表
[This corrects the article DOI: 10.2217/hep.14.7.].
Published Erratum
Hepatic oncology. 2014 Oct;1(4):448. DOI:10.2217/hep.14.37 2014
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma [0.03%]
肝细胞癌系统治疗的影像学疗效评价标准
Francesco Tovoli,Matteo Renzulli,Alessandro Granito et al.
Francesco Tovoli et al.
Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic assessment of its biological activity is a disputed matter as at least five different criteria have been propose...
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives [0.03%]
肝细胞癌早期检测生物标志物研发：现状与未来展望
Shreya Sengupta,Neehar D Parikh
Shreya Sengupta
Early detection of hepatocellular carcinoma (HCC) leads to improved survival; however, current early detection strategies for HCC surveillance are ineffective. Thus, there has been interest in developing biomarkers to aid in the early detec...
Stephanie Klein,Jean-François Dufour
Stephanie Klein
Hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease is becoming more common globally. The incidence of HCC due to nonalcoholic steatohepatitis in comparison to other etiologies is increasing. This is due to the ...
Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity [0.03%]
单中心基于影像的疗效和比较毒性肝内胆管癌不可切除病灶的化学栓塞与放射性微球治疗效果研究
Olaguoke Akinwande,Veer Shah,Abigail Mills et al.
Olaguoke Akinwande et al.
Aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of unresectable intrahepatic cholangiocarcinoma (UICC). Materials & meth...
'Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma [0.03%]
肝细胞癌综合治疗术中的新影像学成功征象：“拥抱征”
Roberto Iezzi,Maurizio Pompili,Eleonora Brigida Annicchiarico et al.
Roberto Iezzi et al.
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. A careful multidisciplinary assessment of tumor characteristics, liver function and physical status is required for proper therapeutic management. In recent year...
Case Reports
Hepatic oncology. 2017 Jul;4(3):69-73. DOI:10.2217/hep-2017-0017 2017
Luca Marzi,Erica Villa
Luca Marzi
Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma [0.03%]
肝动脉及全身化疗联合维持治疗胆管癌
Giammaria Fiorentini,Andrea Mambrini,Donatella Sarti et al.
Giammaria Fiorentini et al.
Aim: The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectabl...
Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib [0.03%]
索拉非尼治疗的肝细胞癌患者血液循环内皮细胞与疾病进展风险的关系研究
Petros Giovanis,Graziano Pianezze,Valter Vincenzi et al.
Petros Giovanis et al.
Aim: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). ...
The TGF-β pathway: a pharmacological target in hepatocellular carcinoma? [0.03%]
TGF-β信号途径：肝癌的药理学靶点？
Isabel Fabregat,Gianluigi Giannelli;IT-LIVER Consortium
Isabel Fabregat